Phase I – Other

1,064 trials 249 recruiting

Filter these 1,064 trials by condition, country, sponsor and more.

Open in Search →

Study of Avelumab in combination with Lenvatinib for children with primary CNS tumors Halted

2024-512940-51-00 Central Nervous System Tumors 2021-11-24
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy in women with advanced ovarian cancer Halted

2024-515996-37-00 peritoneal carcinosis of ovarian origin cancer 2021-07-30
Phase I trial of CArbonic Anhydrase Inhibition in combination with radiochemotherapy or radioimmunotherapy in small cell lung carcinoma (ICA… Halted

2022-503093-36-00 lung carcinoma 2020-01-27
LB−100 and azenosertib in metastatic colorectal cancer patients Suspended

2024-511227-33-00 Metastatic colorectal cancer
Safety and tolerability of medicated chewing gum with sodium alginate, calcium carbonate and sodium bicarbonate. Ended

2025-524102-15-00 No medical condition. 2026-04-29
Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 ar… Ended

2025-525076-29-00 Phase I study in healthy male volunteers. Intended indi 2026-03-23
Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability s… Ended

2026-525256-29-00 Comparative bioavailability study under fasting conditi 2026-03-13
A Study to Track How the Healthy Male Participants Handles the New Oral Drug RO7795081 for Weight Management and Diabetes Ended

2025-524210-28-00 Not Applicable 2026-02-17
A study in healthy men to test how itraconazole influences the amount of BI 764198 in the blood Ended

2025-523135-19-00 Healthy volunteer trial 2026-02-06
A study in healthy people to test whether BI 764198 influences the amount of metformin in the body Ended

2025-522432-14-00 Healthy volunteer trial 2026-02-03
OPEN-LABEL PALATABILITY STUDY OF A NOVEL ORODISPERSIBLE PARACETAMOL/IBUPROFEN FORMULATION AFTER A SINGLE ORAL ADMINISTRATION IN HEALTHY SUBJ… Ended

2025-524274-41-00 Healthy volunteers 2026-01-26
A study in healthy men to test how BI 1584862 is processed in the body Ended

2025-522311-41-00 Healthy volunteer trial 2026-01-22
A study investigating the effect of curcumin on the absorption and elimination of IMU 838, a new compound that may potentially be used in th… Ended

2025-523791-24-00 Multiple sclerosis 2026-01-08
Open-label single dose trial to evaluate pharmacokinetics, safety, and acceptability/palatability of oveporexton in children from 6 years to… Ended

2025-522034-31-00 Narcolepsy with Cataplexy (Narcolepsy Type 1) 2026-01-07
Open label study to investigate patch adhesion of an Esflurbiprofen-containing patch in healthy volunteers Ended

2025-523577-42-00 Patch adhesion trial with healthy subjects, therapeutic 2026-01-06
A study to compare how the body absorbs different formulations of a new medicine, and how food affects drug absorption, in healthy participa… Ended

2025-523430-14-00 Psoriasis 2025-12-24
A study investigating the safety of RO7795074, a new compound that may potentially be used in the treatment of type 1 diabetes, and the effe… Ended

2025-521921-34-00 Overweight or Obese (otherwise healthy) 2025-12-19
Investigating the pharmacokinetics of petrelintide using different drug product concentrations in participants with a BMI ≥27.0 kg/m2 Ended

2025-520598-38-00 Weight reduction 2025-12-17
A study in healthy men and women to test how BI 3000202 is taken up and processed by the body Ended

2023-510345-21-00 Healthy volunteer trial 2025-12-16
Phase 1 study to investigate the pharmacokinetic profile and safety of 3 testosterone gel formulations in postmenopausal female participants… Ended

2025-522726-12-00 No medical conditions. 2025-12-16
A research study of a new medicine NNC0363-1063 in participants with type 1 diabetes Ended

2025-521593-33-00 Diabetes type 1 2025-12-03
A Study Investigating the Safety and Absorption of Different Administration forms of RO7795074, a New Compound that may Potentially be Used … Ended

2025-521888-13-00 Overweight or Obese (otherwise healthy) 2025-12-02
The effect of SYX-5219 on an immune response in the skin. Ended

2025-522217-27-00 Atopic dermatitis (AD) 2025-11-19
A trial to evaluate the absolute bioavailability of cenerimod in healthy male participants Ended

2025-522320-27-00 Not applicable - healthy volunteer trial 2025-11-17